Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Meredith, PA
  • Ostergren, J
  • McMurray, JJV
  • Granger, CB
  • Swedberg, K
  • Yusuf, Salim
  • Michelson, EL
  • Olofsson, B
  • Puu, M
  • Solomon, SD
  • Pfeffer, MA

publication date

  • March 6, 2007